ResearchMoz

Gonorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Publisher Name » GlobalData
Published Date » 2012-03-31
No. Of Pages » 48

GlobalData, the industry analysis specialist, has released its new report, Gonorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Gonorrhea Therapeutics market. The report identifies the key trends shaping and driving the global Gonorrhea Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gonorrhea Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope


The report provides information on the key drivers and challenges of the Gonorrhea Therapeutics market. Its scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gonorrhea Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Gonorrhea Therapeutics market. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gonorrhea Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Gonorrhea Therapeutics market

Reasons to buy


The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Gonorrhea Therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gonorrhea Therapeutics market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Gonorrhea Therapeutics market landscape? Identify, understand and capitalize.
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Gonorrhea - Introduction 6
2.1 Overview 6
2.2 Epidemiology 6
2.3 Etiology 7
2.4 Pathophysiology 7
2.5 Signs and Symptoms 8
2.5.1 Signs and Symptoms in Females 8
2.5.2 Signs and Symptoms in Males 9
2.6 Commonly Used Diagnostic Tests 9
2.7 Treatment and Management Options for Gonorrhea 9
2.8 Prognosis 11
2.9 GlobalData Pipeline Report Guidance 11

3 Gonorrhea Therapeutics - Market Characterization 12
3.1 Gonorrhea Therapeutics Market Size (2006-2011) - Global 12
3.2 Gonorrhea Therapeutics Market Forecast (2011-2019) - Global 13
3.3 Gonorrhea Therapeutics Market Size (2006-2011) - The US 14
3.4 Gonorrhea Therapeutics Market Forecast (2011-2019) - The US 15
3.5 Gonorrhea Therapeutics Market Size (2006-2011) - France 16
3.6 Gonorrhea Therapeutics Market Forecast (2011-2019) - France 17
3.7 Gonorrhea Therapeutics Market Size (2006-2011) - Germany 18
3.8 Gonorrhea Therapeutics Market Forecast (2011-2019) - Germany 19
3.9 Gonorrhea Therapeutics Market Size (2006-2011) - Italy 20
3.10 Gonorrhea Therapeutics Market Forecast (2011-2019) - Italy 21
3.11 Gonorrhea Therapeutics Market Size (2006-2011) - Spain 22
3.12 Gonorrhea Therapeutics Market Forecast (2011-2019) - Spain 23
3.13 Gonorrhea Therapeutics Market Size (2006-2011) - The UK 24
3.14 Gonorrhea Therapeutics Market Forecast (2011-2019) - The UK 25
3.15 Gonorrhea Therapeutics Market Size (2006-2011) - Japan 26
3.16 Gonorrhea Therapeutics Market Forecast (2011-2019) - Japan 27
3.17 Drivers and Barriers for the Gonorrhea Market 28
3.17.1 Gonorrhea Therapeutics Market Drivers 28
3.17.2 Gonorrhea Therapeutics Market Barriers 28
3.18 Opportunity and Unmet Need 29

4 Gonorrhea Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profile Marketed Products in the Gonorrhea Therapeutics Market 32
4.3.1 Cephalosporins 32
4.3.2 Cefixime 32
4.3.3 Ceftriaxone 33
4.3.4 Doxycycline 33
4.3.5 Azithromycin 34
4.4 Key Takeaway 34

5 Gonorrhea Therapeutics - Pipeline Assessment 35

6 Gonorrhea Therapeutics - Clinical Trials Mapping 36

6.1 Clinical Trials by Region/Country (US, EU-5 and Japan) 36
6.2 Clinical Trials by Phase of Clinical Development 36
6.3 Clinical Trials by Trial Status 37
6.4 Clinical Trial by Prominent Sponsors 38
6.5 Clinical Trials by Overall Sponsors 39
6.6 Company Participating in Gonorrhea Therapeutics Clinical Trials 39

7 Gonorrhea Therapeutics - Strategic Assessment 40
7.1 Key Events Impacting the Future Market 40
7.2 Future Market Competition Scenario 41

8 Gonorrhea Therapeutics - Licensing & Partnership Deals 42

9 Gonorrhea Therapeutics - Appendix 43

9.1 Market Definitions 43
9.2 Acronyms 43
9.3 Research Methodology 43
9.3.1 Coverage 44
9.3.2 Secondary Research 44
9.3.3 Forecasting 44
9.3.4 Primary Research 46
9.3.5 Expert Panel Validation 47
9.4 Contact Us 47
9.5 Disclaimer 47
9.6 Bibliography 48

List of Tables


Table 1: Incidence of Gonorrhea 7
Table 2: Treatments Regimens for Gonococcal Infection and Associated Conditions 10
Table 3: Treatments Regimens for Pelvic Inflammatory Disease (PID) 10
Table 4: Gonorrhea Therapeutics Market, Global, Revenue ($m), 20062011 12
Table 5: Gonorrhea Therapeutics, Market, Global, Forecast ($m), 20112019 13
Table 6: Gonorrhea Therapeutics Market, The US, Revenue ($m), 20062011 14
Table 7: Gonorrhea Therapeutics Market, The US, Forecasts ($m), 20112019 15
Table 8: Gonorrhea Therapeutics Market, France, Revenue ($000), 20062011 16
Table 9: Gonorrhea Therapeutics Market, France, Forecasts ($000), 20112019 17
Table 10: Gonorrhea Therapeutics Market, Germany, Revenue ($000), 20062011 18
Table 11: Gonorrhea Therapeutics Market, Germany, Forecasts ($000), 20112019 19
Table 12: Gonorrhea Therapeutics Market, Italy, Revenue ($000), 20062011 20
Table 13: Gonorrhea Therapeutics Market, Italy, Forecasts ($000), 20112019 21
Table 14: Gonorrhea Therapeutics Market, Spain, Revenue ($000), 20062011 22
Table 15: Gonorrhea Therapeutics Market, Spain, Forecasts ($000), 20112019 23
Table 16: Gonorrhea Therapeutics Market, The UK, Revenue ($000), 20062011 24
Table 17: Gonorrhea Therapeutics Market, The UK, Forecasts ($000), 20112019 25
Table 18: Gonorrhea Therapeutics Market, Japan, Revenue ($000), 20062011 26
Table 19: Gonorrhea Therapeutics Market, Japan, Forecasts ($000), 20112019 27
Table 20: Gonorrhea Therapeutics Clinical Trials by Country, 2011 36
Table 21: Gonorrhea Therapeutics, Major Markets Clinical Trials by Phase, 2011 37
Table 22: Gonorrhea Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 37
Table 23: Gonorrhea Therapeutics Prominent Sponsors, 2011 38
Table 24: Gonorrhea Therapeutics Overall Sponsors, 2011 39
Table 25: Gonorrhea Therapeutics, Global, Deals 42

List of Figures


Figure 1: Gonorrhea Therapeutics Market, Global, Revenue ($m), 20062011 12
Figure 2: Gonorrhea Therapeutics Market, Global, Forecast ($m), 20112019 13
Figure 3: Gonorrhea Therapeutics Market, The US, Revenue ($m), 20062011 14
Figure 4: Gonorrhea Therapeutics Market, The US, Forecast ($m), 20112019 15
Figure 5: Gonorrhea Therapeutics Market, France, Revenue ($000), 20062011 16
Figure 6: Gonorrhea Therapeutics Market, France, Forecast ($000), 20112019 17
Figure 7: Gonorrhea Therapeutics Market, Germany, Revenue ($000), 20062011 18
Figure 8: Gonorrhea Therapeutics Market, Germany, Forecast ($000), 20112019 19
Figure 9: Gonorrhea Therapeutics Market, Italy, Revenue ($000), 20062011 20
Figure 10: Gonorrhea Therapeutics Market, Italy, Forecast ($000), 20112019 21
Figure 11: Gonorrhea Therapeutics Market, Spain, Revenue ($000), 20062011 22
Figure 12: Gonorrhea Therapeutics Market, Spain, Forecast ($000), 20112019 23
Figure 13: Gonorrhea Therapeutics Market, The UK, Revenue ($000), 20062011 24
Figure 14: Gonorrhea Therapeutics Market, The UK, Forecast ($000), 20112019 25
Figure 15: Gonorrhea Therapeutics Market, Japan, Revenue ($000), 20062011 26
Figure 16: Gonorrhea Therapeutics Market, Japan, Forecast ($000), 20112019 27
Figure 17: Opportunity and Unmet Need in the Gonorrhea Therapeutics Market 29
Figure 18: Strategic Competitor Assessment, 2011 31
Figure 19: Gonorrhea Therapeutics, Major Markets Clinical Trials by Phase, 2011 36
Figure 20: Gonorrhea Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 37
Figure 21: Gonorrhea Therapeutics, Major Markets, Overall Sponsors, 2011 38
Figure 22: Gonorrhea Therapeutics, Major Markets, Prominent Sponsors, 2011 39
Figure 23: Gonorrhea Therapeutics Market, Drivers and Restraints 2011 40
Figure 24: Implications for Future Market Competition in the Gonorrhea Therapeutics Market, 2011 41
Figure 25: GlobalData Market Forecasting Model 46

Upcoming Reports:

Smart Airports Market - Global Industry Analysis, Market Size, Share, Growth, Trends, And Forecast, 2012 - 2018
By - Transparency Market Research
Airport operations and business models have evolved dramatically over the last two decades to support the explosive growth of the global airline industry. Regulatory reform and deregulation ushered in a new aviation era in North America, as well as in Europe, Asia, and in emerging countries, producing dramatic traffic growth, diversity, and choice for airline passengers.  Shifting demographics, new corporate governance requirements, and emerging and maturing communication technologies are driving new travel patterns that will require innovative business models and...
Merchant-Paid Rewards Market: Industry Analysis, Market Size, Share, Trends, Growth And Forecast, 2011 - 2018
By - Transparency Market Research
Debit card users are increasing in number as compared to credit card users. Use of debit card allows the consumers to save money for future use as they know how much money they have and how much money they have to spend. This trend leads to the growth of merchant paid reward programs. Credit cards do not give customers this privilege as they pay later for whatever they have purchased. Merchant-paid programs persuade customers to use their debit cards rather than credit cards or paper coupons. Merchant paid programs are gaining popularity in the market as it offers...
Neurometabolic Disorders Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Some of the factors driving neurometabolic disorders market are rising incidences of neurometabolic disorders and growing ageing population. Launch of new drugs coupled with the rising awareness among patients and physicians are expected to increase revenues for the neurometabolic disorders industry in the coming years.  Government agencies and private companies are taking extra measures to increase awareness among patients and physicians regarding diseases and their available treatment options. Enzyme replacement therapy (ERT) is currently the available therapeutic...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...